These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
416 related articles for article (PubMed ID: 33002521)
1. Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence. Godino C; Scotti A; Maugeri N; Mancini N; Fominskiy E; Margonato A; Landoni G Int J Cardiol; 2021 Feb; 324():261-266. PubMed ID: 33002521 [TBL] [Abstract][Full Text] [Related]
2. Viral Coagulopathy in Patients With COVID-19: Treatment and Care. Kipshidze N; Dangas G; White CJ; Kipshidze N; Siddiqui F; Lattimer CR; Carter CA; Fareed J Clin Appl Thromb Hemost; 2020; 26():1076029620936776. PubMed ID: 32687449 [TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 infection and thrombotic complications: a narrative review. Moschonas IC; Tselepis AD J Thromb Thrombolysis; 2021 Jul; 52(1):111-123. PubMed ID: 33449290 [TBL] [Abstract][Full Text] [Related]
4. "2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19": reply. Schulman S; Resnick HE J Thromb Haemost; 2024 Sep; 22(9):2672-2673. PubMed ID: 39174231 [No Abstract] [Full Text] [Related]
5. COVID-19 and thrombosis: From bench to bedside. Ali MAM; Spinler SA Trends Cardiovasc Med; 2021 Apr; 31(3):143-160. PubMed ID: 33338635 [TBL] [Abstract][Full Text] [Related]
6. Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis. Gando S; Wada T Shock; 2022 Jan; 57(1):1-6. PubMed ID: 34172612 [TBL] [Abstract][Full Text] [Related]
7. Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. Ortega-Paz L; Capodanno D; Montalescot G; Angiolillo DJ J Am Heart Assoc; 2021 Feb; 10(3):e019650. PubMed ID: 33228447 [TBL] [Abstract][Full Text] [Related]
8. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Abou-Ismail MY; Diamond A; Kapoor S; Arafah Y; Nayak L Thromb Res; 2020 Oct; 194():101-115. PubMed ID: 32788101 [TBL] [Abstract][Full Text] [Related]
9. COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Miesbach W; Makris M Clin Appl Thromb Hemost; 2020; 26():1076029620938149. PubMed ID: 32677459 [TBL] [Abstract][Full Text] [Related]
10. State-of-the-art review - A review on snake venom-derived antithrombotics: Potential therapeutics for COVID-19-associated thrombosis? Kalita B; Saviola AJ; Samuel SP; Mukherjee AK Int J Biol Macromol; 2021 Dec; 192():1040-1057. PubMed ID: 34656540 [TBL] [Abstract][Full Text] [Related]
11. New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Weitz JI; Eikelboom JW; Samama MM Chest; 2012 Feb; 141(2 Suppl):e120S-e151S. PubMed ID: 22315258 [TBL] [Abstract][Full Text] [Related]
12. The Potency of Seaweed Sulfated Polysaccharides for the Correction of Hemostasis Disorders in COVID-19. Kuznetsova TA; Andryukov BG; Makarenkova ID; Zaporozhets TS; Besednova NN; Fedyanina LN; Kryzhanovsky SP; Shchelkanov MY Molecules; 2021 Apr; 26(9):. PubMed ID: 33947107 [TBL] [Abstract][Full Text] [Related]
13. Good practice statements for antithrombotic therapy in the management of COVID-19: Guidance from the SSC of the ISTH. Spyropoulos AC; Connors JM; Douketis JD; Goldin M; Hunt BJ; Kotila TR; Lopes RD; Schulman S; J Thromb Haemost; 2022 Oct; 20(10):2226-2236. PubMed ID: 35906715 [TBL] [Abstract][Full Text] [Related]
14. Anticoagulant treatment in COVID-19: a narrative review. Carfora V; Spiniello G; Ricciolino R; Di Mauro M; Migliaccio MG; Mottola FF; Verde N; Coppola N; J Thromb Thrombolysis; 2021 Apr; 51(3):642-648. PubMed ID: 32809158 [TBL] [Abstract][Full Text] [Related]
15. Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Russo V; Di Maio M; Attena E; Silverio A; Scudiero F; Celentani D; Lodigiani C; Di Micco P Pharmacol Res; 2020 Sep; 159():104965. PubMed ID: 32474087 [TBL] [Abstract][Full Text] [Related]
16. The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases. Acanfora D; Acanfora C; Ciccone MM; Scicchitano P; Bortone AS; Uguccioni M; Casucci G Viruses; 2021 Sep; 13(10):. PubMed ID: 34696334 [TBL] [Abstract][Full Text] [Related]
17. [Improving outcome of COVID-19-associated thrombosis: the need for evaluation of fibrinolytic activation]. Yamada S; Asakura H Rinsho Ketsueki; 2022; 63(5):471-480. PubMed ID: 35662173 [TBL] [Abstract][Full Text] [Related]
18. "2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19": comment from Flumignan et al. Flumignan RLG; Nakano LCU; Amorim JE; Atallah ÁN J Thromb Haemost; 2024 Sep; 22(9):2670-2671. PubMed ID: 39174230 [No Abstract] [Full Text] [Related]
19. [Antithrombotic treatments in patients with SARS-CoV-2 infection: from current evidence to reasonable recommendations - A position paper from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology]. Patti G; Lio V; Cavallari I; Gragnano F; Riva L; Calabrò P; Di Pasquale G; Pengo V; Rubboli A G Ital Cardiol (Rome); 2020 Jul; 21(7):489-501. PubMed ID: 32555564 [TBL] [Abstract][Full Text] [Related]
20. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial. Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]